• Ascentage Pharma Group International filed an automatic shelf registration on Form F-3, including an at-the-market offering of up to USD 200 million of ADSs.
• Entered a sales agreement with Citigroup, Deutsche Bank, and BTIG to sell ADSs on Nasdaq from time to time.
• Each ADS represents four ordinary shares; issuance is expected to stay within the existing general mandate of up to 74,666,950 shares.
• Sales are not expected to start until Hong Kong listing-rule waivers are granted; the waiver application remains pending.
• Proceeds earmarked for commercialization of Olverembatinib and Lisaftoclax, clinical development, working capital, and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260719-12248969), on July 19, 2026, and is solely responsible for the information contained therein.